Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Japan Halitosis Treatment Market

ID: MRFR/MED/54790-HCR
200 Pages
Satyendra Maurya
Last Updated: February 06, 2026

Japan Halitosis Treatment Market Research Report: Size, Share, Trend Analysis By Indication (Respiratory, Liver, Kidney, Gastrointestinal, Systemic, Others), By Diagnostic Tests (Halimeter, Gas Chromatography, BANA Test, -Galactosidase Activity Assay, Others) and By Drug Treatment (Antacids, Antiseptics, Ranitidine, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Japan Halitosis Treatment Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Life Sciences, BY Indication (USD Million)
  49.     4.1.1 Respiratory
  50.     4.1.2 Liver
  51.     4.1.3 Kidney
  52.     4.1.4 Gastrointestinal
  53.     4.1.5 Systemic
  54.     4.1.6 Others
  55.   4.2 Life Sciences, BY Diagnostic Tests (USD Million)
  56.     4.2.1 Halimeter
  57.     4.2.2 Gas Chromatography
  58.     4.2.3 BANA Test
  59.     4.2.4 Β-Galactosidase Activity Assay
  60.     4.2.5 Others
  61.   4.3 Life Sciences, BY Drug Treatment (USD Million)
  62.     4.3.1 Antacids
  63.     4.3.2 Antiseptics
  64.     4.3.3 Ranitidine
  65.     4.3.4 Others
  66. 5 SECTION V: COMPETITIVE ANALYSIS
  67.   5.1 Competitive Landscape
  68.     5.1.1 Overview
  69.     5.1.2 Competitive Analysis
  70.     5.1.3 Market share Analysis
  71.     5.1.4 Major Growth Strategy in the Life Sciences
  72.     5.1.5 Competitive Benchmarking
  73.     5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  74.     5.1.7 Key developments and growth strategies
  75.       5.1.7.1 New Product Launch/Service Deployment
  76.       5.1.7.2 Merger & Acquisitions
  77.       5.1.7.3 Joint Ventures
  78.     5.1.8 Major Players Financial Matrix
  79.       5.1.8.1 Sales and Operating Income
  80.       5.1.8.2 Major Players R&D Expenditure. 2023
  81.   5.2 Company Profiles
  82.     5.2.1 Procter & Gamble (US)
  83.       5.2.1.1 Financial Overview
  84.       5.2.1.2 Products Offered
  85.       5.2.1.3 Key Developments
  86.       5.2.1.4 SWOT Analysis
  87.       5.2.1.5 Key Strategies
  88.     5.2.2 Colgate-Palmolive (US)
  89.       5.2.2.1 Financial Overview
  90.       5.2.2.2 Products Offered
  91.       5.2.2.3 Key Developments
  92.       5.2.2.4 SWOT Analysis
  93.       5.2.2.5 Key Strategies
  94.     5.2.3 Unilever (GB)
  95.       5.2.3.1 Financial Overview
  96.       5.2.3.2 Products Offered
  97.       5.2.3.3 Key Developments
  98.       5.2.3.4 SWOT Analysis
  99.       5.2.3.5 Key Strategies
  100.     5.2.4 Johnson & Johnson (US)
  101.       5.2.4.1 Financial Overview
  102.       5.2.4.2 Products Offered
  103.       5.2.4.3 Key Developments
  104.       5.2.4.4 SWOT Analysis
  105.       5.2.4.5 Key Strategies
  106.     5.2.5 GlaxoSmithKline (GB)
  107.       5.2.5.1 Financial Overview
  108.       5.2.5.2 Products Offered
  109.       5.2.5.3 Key Developments
  110.       5.2.5.4 SWOT Analysis
  111.       5.2.5.5 Key Strategies
  112.     5.2.6 Church & Dwight (US)
  113.       5.2.6.1 Financial Overview
  114.       5.2.6.2 Products Offered
  115.       5.2.6.3 Key Developments
  116.       5.2.6.4 SWOT Analysis
  117.       5.2.6.5 Key Strategies
  118.     5.2.7 Henkel (DE)
  119.       5.2.7.1 Financial Overview
  120.       5.2.7.2 Products Offered
  121.       5.2.7.3 Key Developments
  122.       5.2.7.4 SWOT Analysis
  123.       5.2.7.5 Key Strategies
  124.     5.2.8 Listerine (US)
  125.       5.2.8.1 Financial Overview
  126.       5.2.8.2 Products Offered
  127.       5.2.8.3 Key Developments
  128.       5.2.8.4 SWOT Analysis
  129.       5.2.8.5 Key Strategies
  130.   5.3 Appendix
  131.     5.3.1 References
  132.     5.3.2 Related Reports
  133. 6 LIST OF FIGURES
  134.   6.1 MARKET SYNOPSIS
  135.   6.2 JAPAN MARKET ANALYSIS BY INDICATION
  136.   6.3 JAPAN MARKET ANALYSIS BY DIAGNOSTIC TESTS
  137.   6.4 JAPAN MARKET ANALYSIS BY DRUG TREATMENT
  138.   6.5 KEY BUYING CRITERIA OF LIFE SCIENCES
  139.   6.6 RESEARCH PROCESS OF MRFR
  140.   6.7 DRO ANALYSIS OF LIFE SCIENCES
  141.   6.8 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
  142.   6.9 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
  143.   6.10 SUPPLY / VALUE CHAIN: LIFE SCIENCES
  144.   6.11 LIFE SCIENCES, BY INDICATION, 2024 (% SHARE)
  145.   6.12 LIFE SCIENCES, BY INDICATION, 2024 TO 2035 (USD Million)
  146.   6.13 LIFE SCIENCES, BY DIAGNOSTIC TESTS, 2024 (% SHARE)
  147.   6.14 LIFE SCIENCES, BY DIAGNOSTIC TESTS, 2024 TO 2035 (USD Million)
  148.   6.15 LIFE SCIENCES, BY DRUG TREATMENT, 2024 (% SHARE)
  149.   6.16 LIFE SCIENCES, BY DRUG TREATMENT, 2024 TO 2035 (USD Million)
  150.   6.17 BENCHMARKING OF MAJOR COMPETITORS
  151. 7 LIST OF TABLES
  152.   7.1 LIST OF ASSUMPTIONS
  153.     7.1.1
  154.   7.2 Japan MARKET SIZE ESTIMATES; FORECAST
  155.     7.2.1 BY INDICATION, 2025-2035 (USD Million)
  156.     7.2.2 BY DIAGNOSTIC TESTS, 2025-2035 (USD Million)
  157.     7.2.3 BY DRUG TREATMENT, 2025-2035 (USD Million)
  158.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  159.     7.3.1
  160.   7.4 ACQUISITION/PARTNERSHIP
  161.     7.4.1

Japan Life Sciences Market Segmentation

Life Sciences By Indication (USD Million, 2025-2035)

  • Respiratory
  • Liver
  • Kidney
  • Gastrointestinal
  • Systemic
  • Others

Life Sciences By Diagnostic Tests (USD Million, 2025-2035)

  • Halimeter
  • Gas Chromatography
  • BANA Test
  • Β-Galactosidase Activity Assay
  • Others

Life Sciences By Drug Treatment (USD Million, 2025-2035)

  • Antacids
  • Antiseptics
  • Ranitidine
  • Others

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions